Import of global high-risk clones is the primary driver of carbapenemase-producing Pseudomonas aeruginosa in Norway
Journal of Medical Microbiology · 2025
DOI: 10.1099/jmm.0.001944 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medical Microbiology, 2025. Verfasst von Bjørg Christina Haldorsen und 7 weiteren Autor:innen. Beteiligte Einrichtung: Norwegian Centre for Detection of Antimicrobial Resistance, Department of Microbiology and Infection Control, University Hospital of North Norway, Tr…. Hauptthemen laut MEDLINE: beta-Lactamases, Pseudomonas aeruginosa, Bacterial Proteins, Pseudomonas Infections. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universitetssykehuset Nord-Norge.
Abstract (Originalsprache)
Introduction
Infections by carbapenemase-producing Pseudomonas aeruginosa (CP-Pa) are concerning due to limited treatment options. The emergence of multidrug-resistant (MDR) high-risk clones is an essential driver in the global rise of CP-Pa. Hypothesis/Gap Statement. Insights into the molecular epidemiology of CP-Pa are crucial to understanding its clinical and public health impact. Despite the low incidence of infections in Norway, global spread requires an understanding of regional dissemination patterns.
Aim
This study aimed to investigate the phenotypic and genotypic characteristics of CP-Pa isolates in Norway and molecular epidemiology by utilizing available metadata. Methodology. The study collection comprised all verified CP-Pa isolated in Norway from 2006 to 2022 ( n =67) obtained from clinical (75%; n =50) or screening samples (22%; n =15) or had no available information (3%; n =2). Phenotypic analyses included antimicrobial susceptibility testing against clinically relevant antipseudomonal antibiotics and comparative testing for carbapenemase production using three different methods ( β -CARBA, IMI/IMD gradient test and Coris O.K.N.V.I RESIST-5). Whole-genome sequencing was performed to identify virulence factors, resistance determinants and genomic relatedness.
Results
The isolates were categorized as MDR ( n =39) encoding Verona integron-encoded metallo- β -lactamase (VIM) ( n =28), New Delhi metallo- β -lactamase (NDM) ( n =6), imipenemase metallo- β -lactamase (IMP) ( n =4) or Guiana extended spectrum metallo- β -lactamase ( n =1) carbapenemases or extensively drug-resistant (XDR; n= 28) encoding VIM ( n =11), NDM ( n =9) or IMP ( n =8) carbapenemases. CP-Pa numbers ranged from 1 to 7 annually, peaking at 17 in 2022. Most isolates ( n =64) were associated with international travel or hospitalization abroad. Phylogenetic analyses identified nine clusters of closely related genomes, with one suspected case of domestic patient-to-patient transmission. Among 21 detected sequence types, several were global high-risk clones, including ST235 ( n =12), ST111 ( n =9), ST773 ( n =9), ST253 ( n =3), ST357 ( n =3), ST395 ( n =3), ST823 ( n =3), ST233 ( n =2), ST654 ( n =2), ST260 ( n =1) and ST308 ( n =1), covering 72% of the Norwegian isolates. ST1047 (IMP-1) and ST773 (NDM-1) were associated with Ukrainian war victims. Carbapenemase detection rates for phenotypic tests were 88% ( β -CARBA), 91% (IMI/IMD) and 94% (Coris) in our collection.
Conclusion
The study highlights the low incidence yet high genomic diversity of CP-Pa in Norway and the dominance of high-risk clones linked to imports, contributing to the high proportion of XDR.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Norwegian Centre for Detection of Antimicrobial Resistance, Department of Microbiology and Infection Control, University Hospital of North Norway, Tromsø, Norway.
- Department for Infection Control and Preparedness, Norwegian Institute of Public Health, Oslo, Norway.
- Department of Medical Biology, Faculty of Health Sciences, UiT - The Arctic University of Norway, Tromsø, Norway.
Förderung
- Universitetssykehuset Nord-Norge
Zitieren
APA
Haldorsen, B. C., Samuelsen, Ø., Janice, J., Sare, M., Molvik, M., Sundsfjord, A., The Norwegian Study Group On Cp-Pa, & Pedersen, T. (2025). Import of global high-risk clones is the primary driver of carbapenemase-producing Pseudomonas aeruginosa in Norway. Journal of Medical Microbiology. https://doi.org/10.1099/jmm.0.001944
Vancouver
Haldorsen BC, Samuelsen Ø, Janice J, Sare M, Molvik M, Sundsfjord A, et al. Import of global high-risk clones is the primary driver of carbapenemase-producing Pseudomonas aeruginosa in Norway. Journal of Medical Microbiology. 2025. doi:10.1099/jmm.0.001944
BibTeX
@article{Haldorsen2025,
author = {Haldorsen, Bjørg Christina and Samuelsen, Ørjan and Janice, Jessin and Sare, Miriam and Molvik, Mari and Sundsfjord, Arnfinn and The Norwegian Study Group On Cp-Pa and Pedersen, Torunn},
title = {Import of global high-risk clones is the primary driver of carbapenemase-producing Pseudomonas aeruginosa in Norway},
journal = {Journal of Medical Microbiology},
year = {2025},
doi = {10.1099/jmm.0.001944}
}
EUVIMED